Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Fail First/ Step Therapy Advocacy Update

Sep 26// Advocates in the news

We want to share a quick update and applaud one of our 50-State Network advocates Danielle Yevsa who spoke up about Fail First/ Step Therapy practices in the New York Daily News.

READ MORE

8/3/16 – New York Step Therapy Campaign Rally

Aug 05// Events

Patients, advocates and health care providers came together on the steps of the state capitol in Albany, NY, August 3rd, to call on Governor Andrew Cuomo to sign into law legislation aimed at ensuring that patients and their doctors have the final say in their medication treatment plans. During this past legislative session, both the […]

READ MORE

GHLF/50-SN activity at FDA Arthritis Advisory Committee Meeting July 12th & July 13th

Jul 18// Events

On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]

READ MORE

Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Jul 18// GHLF in the news

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

READ MORE

July 12th – GHLF testimony and recommendation to FDA on proposed biosimilar to HUMIRA (adalimumab)

Jul 15// FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE

July 13th – GHLF FDA Arthritis Advisory Committee comments on proposed biosimilar to ENBREL (etanercept)

Jul 15// FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE

FDA advisory committee unanimously recommends approval of biosimilar to Enbrel – Perspective by Seth Ginsberg

Jul 15// GHLF in the news

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.

READ MORE

Biosimilar Confidence: Patient Perspectives on a New Medication Class – Seth Ginsberg

Jul 15// GHLF in the news

Imagine you’ve been living with rheumatoid arthritis for more than ten years.

READ MORE

Victory in Missouri

Jun 09// Victories

At its core, HB 1366 boils down to two words: Trust and transparency.

READ MORE

GHLF Supports OH HB 505

Apr 19// Letters and Testimony

HB 505 takes positive steps toward updating Ohio law to cover biologics and biosimilars in a
way that protects patients. As you know, unlike traditional chemical drugs, biologics are unique,
complex structures made from living cells that are not easily replicated. A small change or
difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

READ MORE